These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21504378)

  • 1. Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.
    Cal LA; Maso LD; Caielli P; Pagnin E; Fusaro M; Davis PA; Pessina AC
    Blood Press; 2011 Dec; 20(6):376-82. PubMed ID: 21504378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients.
    Calò LA; Dal Maso L; Pagnin E; Ravarotto V; Facco M; Boscaro E; Maiolino G; Pessina AC; Rossi GP
    J Hypertens; 2014 Jan; 32(1):193-9. PubMed ID: 24309489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling.
    Ravarotto V; Pagnin E; Maiolino G; Fragasso A; Carraro G; Rossi B; Calò LA
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1245-50. PubMed ID: 26240115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
    Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
    Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olmesartan, an angiotensin II receptor blocker inhibits the progression of cataract formation in cadmium chloride induced hypertensive albino rats.
    Choudhary R; Bodakhe SH
    Life Sci; 2016 Dec; 167():105-112. PubMed ID: 27744053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Early Normotension with Olmesartan on Rho-kinase Activity in Hypertensive Patients.
    Cantin C; Jalil JE; Bulnes JF; Novoa U; MacNab P; Godoy I; Córdova S; Gabrielli L; Ocaranza MP
    Curr Vasc Pharmacol; 2020; 18(1):87-91. PubMed ID: 30663569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
    Smith RD; Yokoyama H; Averill DB; Cooke L; Brosnihan KB; Schiffrin EL; Ferrario CM
    Am J Cardiovasc Drugs; 2006; 6(5):335-42. PubMed ID: 17083268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis patients.
    Calo LA; Vertolli U; Davis PA; Maso LD; Pagnin E; Ravarotto V; Maiolino G; Lupia M; Seccia TM; Rossi GP
    Clin Nutr; 2014 Jun; 33(3):437-42. PubMed ID: 23845383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
    Rosenbaum D; Girerd X
    Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
    Chrysant SG; Chavanu KJ; Xu J
    Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients.
    Calò LA; Bertipaglia L; Pagnin E; Davis PA; Sartori M; Semplicini A; Pessina AC
    Clin Exp Hypertens; 2006 Feb; 28(2):181-8. PubMed ID: 16546843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
    Chrysant SG; Marbury TC; Silfani TN
    Blood Press Monit; 2006 Jun; 11(3):135-41. PubMed ID: 16702822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
    Mallion JM; Heagerty A; Laeis P
    J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients.
    Hermida RC; Ayala DE; Chayan L; Mojon A; Fernandez JR
    Chronobiol Int; 2009 Jan; 26(1):61-79. PubMed ID: 19142758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology-based assessment of vitamin E-coated dialyzer effects on oxidative stress, inflammation, and vascular remodeling.
    Calò LA; Naso A; D'Angelo A; Pagnin E; Zanardo M; Puato M; Rebeschini M; Landini S; Feriani M; Perego A; Malagoli A; Zagatti R; Calzavara P; Cascone C; Davis PA
    Artif Organs; 2011 Feb; 35(2):E33-9. PubMed ID: 21323683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan.
    Tada Y; Yagi K; Uno M; Matsushita N; Kanematsu Y; Kuwayama K; Shimada K; Nishi K; Hirasawa M; Satomi J; Kitazato KT; Kageji T; Matsuura E; Nagahiro S
    J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1487-92. PubMed ID: 25891757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
    Chrysant SG
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):887-95. PubMed ID: 19673666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.
    Mori H; Yamamoto H; Ukai H; Yuasa S; Nakajima K; Mikawa T; Niizuma M; Hirao K; Umemura S;
    Hypertens Res; 2013 Mar; 36(3):202-7. PubMed ID: 23013888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between oxidative stress, activator protein-1, inflammatory, total antioxidant status and artery stiffness and the efficacy of olmesartan in elderly patients with mild-to-moderate essential hypertension.
    Liu Q; Han L; Du Q; Zhang M; Zhou S; Shen X
    Clin Exp Hypertens; 2016; 38(4):365-9. PubMed ID: 27159403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.